Cite this answer
Retinalamin: quick citable summary
Retinalamin is listed by PeptaHub as a other peptide with a research only legal-status classification. The page summarizes mechanism, research context, common routes, safety notes, and references for writers and AI answer engines.
PeptaHub. “Retinalamin: Mechanism, Research Context, Safety.” peptahub.com, 2026. https://peptahub.com/peptides/retinalamin. Licensed CC BY 4.0.
License: Creative Commons Attribution 4.0 International. Link back to https://peptahub.com/peptides/retinalamin.
What is Retinalamin?
Retinalamin is a bovine retinal polypeptide registered in Russia for retinal degenerative disease. Uncontrolled Russian series report visual acuity gains, but the one randomized animal experiment, in rabbits, found no neuroprotective effect. No human RCT exists.
Overview
Retinalamin is a polypeptide preparation isolated from bovine retinal tissue and registered as a pharmaceutical drug in Russia for retinal degenerative disease. It is the primary ocular bioregulator in the Khavinson peptide system. Its human evidence is limited to uncontrolled Russian series in diabetic retinopathy, inherited retinal abiotrophy and ocular tuberculosis, and the only randomized animal experiment testing it was negative.
Mechanism of action
Retinalamin is a complex of water-soluble polypeptide fractions with molecular weight below 10,000 Da, isolated from bovine retina. The mechanism attributed to it in Russian product literature is activation of ocular tissue metabolism, improved protein synthesis and regulation of lipid peroxidation in photoreceptor and pigment epithelial cells, improved interaction between the retinal pigment epithelium and photoreceptor outer segments, and normalized retinal vascular permeability. These are proposed mechanisms rather than measured ones. No study demonstrating any of them was located, and a randomized rabbit experiment testing retinoprotection directly found no effect on electroretinography or retinal histology.
Reported study ranges
| Purpose | Route | Reported range | Frequency | Notes |
|---|---|---|---|---|
| retinal degeneration research | intramuscular | 5–10 mg | daily for 10 days | Standard Russian clinical protocol: 5–10 mg IM daily for 10 days, repeated 2–3 times per year. Dissolve in 1–2 mL sterile saline. |
Reported ranges are for research context only. Consult a qualified healthcare professional before using any peptide.
Convert Retinalamin research-range units
Need to convert mg to mcg, dose volume, or U-100 syringe units? The Retinalamin dose calculator is preloaded with these ranges, or use the general dose unit converter.
Research summary
The human evidence is two uncontrolled or non-randomized Russian-language series. Trofimova and Khavinson (Vestn Oftalmol 2001) gave combined bioregulatory therapy (retinalamin plus epithalamin plus cortexin) to 104 diabetic retinopathy patients against 42 controls and reported improved visual acuity in 90% of cases along with reduced macular edema. Because three peptides were given together, no effect can be attributed to retinalamin alone, and the study was not randomized or masked. Khvatova and colleagues (Vestn Oftalmol 2005) treated 33 children aged 4 to 7 with retinal abiotrophy and reported improved visual acuity in 82% and enlarged visual fields in 54%, again uncontrolled. A separate series covered retinalamine in ocular tuberculosis. Importantly, the one controlled animal experiment is negative: Suetov and colleagues (Vestn Oftalmol 2021) randomized 36 rabbits into retinalamin and saline groups in a photochemical retinal damage model and found no significant functional or morphological difference between them on electroretinography or histology. No randomized controlled trial in humans exists. Retinalamin is registered in Russia as a retinoprotective pharmaceutical.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Retinalamin for synergistic effects.
Legal status
Registered pharmaceutical in Russia for retinal degenerative diseases. Not FDA-approved. Available in Western markets as a research chemical only. Cannot be sold or prescribed for therapeutic purposes in the US or EU.
Sourcing & access
Research compound
Retinalamin is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Retinalamin is a polypeptide preparation isolated from bovine retinal tissue and registered as a pharmaceutical drug in Russia. It is the primary ocular bioregulator in the Khavinson peptide system. The indications it is used for in Russia are broader than its published evidence, which covers diabetic retinopathy, inherited retinal abiotrophy and ocular tuberculosis in uncontrolled series.
Retinalamin contains water-soluble polypeptide fractions under 10,000 Da. Its manufacturer describes activation of ocular tissue metabolism, improved protein synthesis in photoreceptor and pigment epithelial cells, and normalized retinal vascular permeability. None of that has been demonstrated in a located study, and a randomized rabbit experiment found no retinoprotective effect.
Reported side effects include injection site pain and rare transient visual disturbances. The long-term safety profile is not well characterized in Western literature. It is a registered pharmaceutical in Russia but is not FDA-approved and is available in Western markets only as a research substance.
Two uncontrolled Russian-language series: 104 diabetic retinopathy patients given retinalamin together with epithalamin and cortexin, with visual acuity improved in 90% (three peptides at once, so retinalamin's own contribution is unknown), and 33 children with retinal abiotrophy with visual acuity improved in 82%. Neither was randomized. The one randomized animal experiment, in 36 rabbits with photochemical retinal damage, found no significant benefit over saline on electroretinography or histology. No human randomized trial has been done.
Research references
- [Effectiveness of bio-regulators in the treatment of diabetic retinopathy] (Russian-language; retinalamin given together with epithalamin and cortexin)PubMed
- [Polypeptide bioregulators in the treatment of different-type abiotrophy of the retina] (Russian-language; 33 children aged 4-7, uncontrolled)PubMed
- [Treatment with the peptide bioregulator retinalamine in patients with tuberculosis of the organ of vision] (Russian-language)PubMed
- [Retinoprotective effects of Retinalamin studied in an experimental model of photochemical damage to rabbit retinas] (Russian-language; NEGATIVE result, no significant benefit vs saline)PubMed